Access monitoring does not really improve outcomes

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

It is widely accepted that hemodialysis access monitoring combined with preemptive percutaneous transluminal angioplasty (PTA) improves outcomes. The many studies that have evaluated monitoring during the last decade provide an opportunity to examine whether this hypothesis is valid. Because synthetic grafts are more likely than autogenous arteriovenous fistulas to benefit from monitoring, this review is restricted to grafts. Recent studies show that monitoring does not accurately predict graft thrombosis or failure, nor does it prolong graft life. However, monitoring can reduce thrombosis, and thereby reduce access-related hospitalizations and use of central venous dialysis catheters. Because preemptive PTA is expensive, however, monitoring does not reduce the cost of access-related care. The limited benefit that monitoring provides emphasizes the urgent need to develop better approaches to solving the problem of graft thrombosis and failure.

Original languageEnglish (US)
Pages (from-to)50-56
Number of pages7
JournalBlood Purification
Volume23
Issue number1
DOIs
StatePublished - Jan 20 2005

Fingerprint

Transplants
Thrombosis
Angioplasty
Central Venous Catheters
Arteriovenous Fistula
Renal Dialysis
Dialysis
Hospitalization
Costs and Cost Analysis

Keywords

  • Access surveillance
  • Blood flow
  • Blood vessel prosthesis
  • Hemodialysis
  • Stenosis
  • Synthetic graft
  • Thrombosis
  • Vascular access
  • Vascular resistance

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this

Access monitoring does not really improve outcomes. / Paulson, William D.

In: Blood Purification, Vol. 23, No. 1, 20.01.2005, p. 50-56.

Research output: Contribution to journalReview article

@article{583a210ed5054d3781e091b3b6a3d126,
title = "Access monitoring does not really improve outcomes",
abstract = "It is widely accepted that hemodialysis access monitoring combined with preemptive percutaneous transluminal angioplasty (PTA) improves outcomes. The many studies that have evaluated monitoring during the last decade provide an opportunity to examine whether this hypothesis is valid. Because synthetic grafts are more likely than autogenous arteriovenous fistulas to benefit from monitoring, this review is restricted to grafts. Recent studies show that monitoring does not accurately predict graft thrombosis or failure, nor does it prolong graft life. However, monitoring can reduce thrombosis, and thereby reduce access-related hospitalizations and use of central venous dialysis catheters. Because preemptive PTA is expensive, however, monitoring does not reduce the cost of access-related care. The limited benefit that monitoring provides emphasizes the urgent need to develop better approaches to solving the problem of graft thrombosis and failure.",
keywords = "Access surveillance, Blood flow, Blood vessel prosthesis, Hemodialysis, Stenosis, Synthetic graft, Thrombosis, Vascular access, Vascular resistance",
author = "Paulson, {William D.}",
year = "2005",
month = "1",
day = "20",
doi = "10.1159/000082011",
language = "English (US)",
volume = "23",
pages = "50--56",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Access monitoring does not really improve outcomes

AU - Paulson, William D.

PY - 2005/1/20

Y1 - 2005/1/20

N2 - It is widely accepted that hemodialysis access monitoring combined with preemptive percutaneous transluminal angioplasty (PTA) improves outcomes. The many studies that have evaluated monitoring during the last decade provide an opportunity to examine whether this hypothesis is valid. Because synthetic grafts are more likely than autogenous arteriovenous fistulas to benefit from monitoring, this review is restricted to grafts. Recent studies show that monitoring does not accurately predict graft thrombosis or failure, nor does it prolong graft life. However, monitoring can reduce thrombosis, and thereby reduce access-related hospitalizations and use of central venous dialysis catheters. Because preemptive PTA is expensive, however, monitoring does not reduce the cost of access-related care. The limited benefit that monitoring provides emphasizes the urgent need to develop better approaches to solving the problem of graft thrombosis and failure.

AB - It is widely accepted that hemodialysis access monitoring combined with preemptive percutaneous transluminal angioplasty (PTA) improves outcomes. The many studies that have evaluated monitoring during the last decade provide an opportunity to examine whether this hypothesis is valid. Because synthetic grafts are more likely than autogenous arteriovenous fistulas to benefit from monitoring, this review is restricted to grafts. Recent studies show that monitoring does not accurately predict graft thrombosis or failure, nor does it prolong graft life. However, monitoring can reduce thrombosis, and thereby reduce access-related hospitalizations and use of central venous dialysis catheters. Because preemptive PTA is expensive, however, monitoring does not reduce the cost of access-related care. The limited benefit that monitoring provides emphasizes the urgent need to develop better approaches to solving the problem of graft thrombosis and failure.

KW - Access surveillance

KW - Blood flow

KW - Blood vessel prosthesis

KW - Hemodialysis

KW - Stenosis

KW - Synthetic graft

KW - Thrombosis

KW - Vascular access

KW - Vascular resistance

UR - http://www.scopus.com/inward/record.url?scp=11444255023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11444255023&partnerID=8YFLogxK

U2 - 10.1159/000082011

DO - 10.1159/000082011

M3 - Review article

VL - 23

SP - 50

EP - 56

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 1

ER -